Topic: Chutes and Ladders
As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.
Less than two years after jumping ship from the FDA to AstraZeneca, Badrul Chowdhury, M.D., Ph.D., is leaving the Big Pharma.
Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.
Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.
Abbott CEO White set to step down after 21 years; Lonza head Funk out after just a year; Progenics' Baker could be out after board shuffle.
Teva picks Flex's Kalif to replace CFO McClellan; Endo head Campanelli heads out; Hahn gets pick to be FDA chief.
After three full business days in the position, an abrupt about-face has LabCorp Diagnostics’ CEO John Ratliff heading for the exit.
As Japanese pharma Takeda keeps divesting assets, its new big biotech buy Shire keeps divesting research executives.
Roche Diagnostics nabs Sause to head North American ops; Hung founds new biotech Nuvation; Sonde Health taps Liu as CEO.
Roche Diagnostics has lured back Matthew Sause from Gilead Sciences to be president and CEO of its North American operations.